Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (HZN-7734) for the Treatment of Alopecia Areata
DUBLIN–(BUSINESS WIRE)–Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2, open-label, proof-of-concept trial to evaluate its development-stage medicine daxdilimab (HZN-7734), a potentially first-in-class, fully human monoclonal antibody targeting immunoglobulin-like transcript 7 (ILT7), to treat people with moderate-to-severe alopecia areata. Alopecia areata is a common, acute onset autoimmune disorder … [Read more…]
